Stock CSL CSL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials CSL Limited

Equities

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 02:10:14 2024-05-09 am EDT 		5-day change 1st Jan Change
277 AUD -1.02% Intraday chart for CSL Limited +0.93% -3.35%
03:14am Australian shares retreat as miners, banks drag; CBA down on lower profit RE
May. 07 Australia's CSL tests 'dynamic pricing' of donor blood amid cost surge RE

Valuation

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 68,373 89,914 97,314 89,378 89,111 88,912 - -
Enterprise Value (EV) 1 72,378 94,712 101,308 88,599 99,790 98,739 97,582 96,100
P/E ratio 35.7 x 42.9 x 41 x 38.7 x 40.8 x 32.5 x 27 x 23.3 x
Yield 1.23% 1.02% 1.04% 1.2% 1.28% 1.44% 1.68% 1.93%
Capitalization / Revenue 8.01 x 9.83 x 9.44 x 8.46 x 6.7 x 6.04 x 5.57 x 5.19 x
EV / Revenue 8.48 x 10.4 x 9.83 x 8.39 x 7.5 x 6.7 x 6.12 x 5.61 x
EV / EBITDA 25.1 x 30.2 x 27.2 x 24.6 x 25.6 x 20.1 x 17.8 x 15.5 x
EV / FCF 137 x 73.9 x 41.8 x 57.2 x 72.7 x 45.2 x 33.7 x 26.6 x
FCF Yield 0.73% 1.35% 2.39% 1.75% 1.38% 2.21% 2.97% 3.75%
Price to Book 13 x 13.8 x 11.6 x 6.13 x 5.64 x 4.96 x 4.49 x 4.03 x
Nbr of stocks (in thousands) 453,139 454,049 455,126 481,706 482,372 483,253 - -
Reference price 2 150.9 198.0 213.8 185.5 184.7 184.0 184.0 184.0
Announcement Date 8/13/19 8/18/20 8/17/21 8/16/22 8/14/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 8,539 9,151 10,310 10,562 13,310 14,728 15,954 17,124
EBITDA 1 2,879 3,136 3,720 3,596 3,900 4,909 5,493 6,206
EBIT 1 2,504 2,716 3,130 2,927 3,069 4,224 4,770 5,460
Operating Margin 29.33% 29.69% 30.36% 27.72% 23.06% 28.68% 29.9% 31.89%
Earnings before Tax (EBT) 1 2,341 2,573 2,963 2,780 2,663 3,642 4,285 4,957
Net income 1 1,919 2,102 2,375 2,255 2,194 2,714 3,266 3,788
Net margin 22.47% 22.98% 23.04% 21.35% 16.48% 18.43% 20.47% 22.12%
EPS 2 4.226 4.615 5.210 4.800 4.530 5.662 6.806 7.909
Free Cash Flow 1 526.8 1,282 2,426 1,550 1,373 2,185 2,896 3,608
FCF margin 6.17% 14% 23.53% 14.67% 10.32% 14.84% 18.15% 21.07%
FCF Conversion (EBITDA) 18.3% 40.86% 65.21% 43.1% 35.21% 44.51% 52.73% 58.13%
FCF Conversion (Net income) 27.46% 60.95% 102.13% 68.74% 62.58% 80.5% 88.66% 95.24%
Dividend per Share 2 1.850 2.020 2.220 2.220 2.360 2.658 3.099 3.560
Announcement Date 8/13/19 8/18/20 8/17/21 8/16/22 8/14/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 4,911 4,240 5,739 4,571 6,041 4,521 7,184 6,126 8,053 6,656
EBITDA 1 1,836 1,300 2,638 1,081 2,479 1,117 2,516 1,384 3,042 2,146
EBIT 1 1,632 1,084 2,358 772 2,215 712.7 2,134 934.7 2,795 1,551
Operating Margin 33.23% 25.58% 41.09% 16.89% 36.67% 15.77% 29.71% 15.26% 34.71% 23.3%
Earnings before Tax (EBT) 1,561 1,011 2,251 712.1 2,145 635.2 1,963 - 2,379 -
Net income 1 1,248 854.5 1,810 565 1,760 494.4 1,623 570.8 1,901 781.5
Net margin 25.41% 20.15% 31.54% 12.36% 29.13% 10.94% 22.6% 9.32% 23.61% 11.74%
EPS 2.740 1.875 3.980 1.230 3.850 0.9600 3.370 - 3.920 -
Dividend per Share 2 0.9500 1.070 1.040 1.180 1.040 1.180 1.070 1.290 1.190 1.360
Announcement Date 2/11/20 8/18/20 2/17/21 8/17/21 2/15/22 8/16/22 2/13/23 8/14/23 2/12/24 -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 4,005 4,798 3,993 - 10,679 9,827 8,669 7,188
Net Cash position 1 - - - 779 - - - -
Leverage (Debt/EBITDA) 1.391 x 1.53 x 1.074 x - 2.738 x 2.002 x 1.578 x 1.158 x
Free Cash Flow 1 527 1,282 2,426 1,550 1,373 2,185 2,896 3,608
ROE (net income / shareholders' equity) 41.1% 35.7% 31.9% 19.6% 14.5% 17.2% 18% 19%
ROA (Net income/ Total Assets) 16.6% 15.1% 14.1% 9.7% 6.79% 8.76% 9.72% 10.7%
Assets 1 11,544 13,890 16,886 23,252 32,290 30,984 33,594 35,385
Book Value Per Share 2 11.60 14.40 18.40 30.30 32.70 37.10 41.00 45.60
Cash Flow per Share 2 3.620 5.460 7.940 5.590 5.380 5.940 7.850 9.660
Capex 1 1,118 1,207 1,196 1,079 1,228 877 982 1,028
Capex / Sales 13.09% 13.19% 11.6% 10.21% 9.23% 5.96% 6.16% 6%
Announcement Date 8/13/19 8/18/20 8/17/21 8/16/22 8/14/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for CSL Limited

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
184 USD
Average target price
199.6 USD
Spread / Average Target
+8.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-3.35% 88.91B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+4.08% 41.25B
BIOGEN INC. Stock Biogen Inc.
-15.09% 31.99B
UCB Stock UCB
+52.98% 24.73B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.13% 15.54B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-8.63% 12.05B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-40.39% 12.07B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.22% 8.84B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-5.15% 8.3B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
-6.45% 7.07B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CSL Stock
  4. Financials CSL Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW